Low vitamin D as a risk factor for the development of myalgia in patients taking high-dose simvastatin: A retrospective review

Clinical Therapeutics

Volumn 36, Issue 5, 2014, Pages 770-777

  Mergenhagen, Kari ^a   Ott, Michael ^b   Heckman, Kerry ^a   Rubin, Lisa M ^a   Kellick, Kenneth ^a  

^a VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

^b ERIE COUNTY MEDICAL CENTER   (United States)

Author keywords

muscle pain; myalgia; myopathy; rhabdomyolysis; simvastatin; statins; vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALANINE AMINOTRANSFERASE; AMIODARONE; AMLODIPINE; ATORVASTATIN; COLCHICINE; COLECALCIFEROL; DIGOXIN; DILTIAZEM; ERGOCALCIFEROL; FIBRIC ACID DERIVATIVE; FORMOTEROL; IPRATROPIUM BROMIDE PLUS SALBUTAMOL; LISINOPRIL; MACROLIDE; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VERAPAMIL; VITAMIN D;

ADULT; AGED; ALCOHOLISM; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG MEGADOSE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYALGIA; MYOPATHY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; VETERAN; BLOOD; CHEMICALLY INDUCED; COMPLICATION; DOSE RESPONSE; MEDICAL RECORD; MUSCLE DISEASE; STATISTICAL MODEL; VITAMIN D DEFICIENCY; YOUNG ADULT;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LOGISTIC MODELS; MALE; MEDICAL RECORDS; MIDDLE AGED; MUSCULAR DISEASES; MYALGIA; RETROSPECTIVE STUDIES; RHABDOMYOLYSIS; RISK FACTORS; SIMVASTATIN; VITAMIN D; VITAMIN D DEFICIENCY; YOUNG ADULT;

EID: 84901440042     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.02.023     Document Type: Article

References (16)

1. The Use of Medicines in the United States: Review of 2010. http://www.imshealth.com/imshealth/Global/Content/IMSInstitute/Documents/ IHII-UseOfMed-report.pdf. 2011; http://www.imshealth.com/imshealth/Global/ Content/IMS/Institute/Documents/IHII-UseOfMed-report.pdf. Accessed August 1, 2011.
2. FDA: Limit Use of 80 mg Simvastatin. United States Food and Drug Administration. Consumer Updates. 2011. http://www.fda.gov/forconsumers/ consumerupdates/ucm257884.htm. Accessed June 8, 2011.
3. J. Armitage, L. Bowman, and K. Wallendszus et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial Lancet 376 2010 1658 1669
4. Simvastatin. Hudson, OH: Lexi-Comp Inc; 2012.
5. R.C. Pasternak, S.C. Smith Jr, C.N. Bairey-Merz, S.M. Grundy, J.I. Cleeman, and C. Lenfant ACC/AHA/NHLBI clinical advisory on the use and safety of statins Stroke 33 2002 2337 2341
6. M.L. Thompson Selection of variables in multiple regression, part I: a review and evaluation Int Stat Rev 46 1978 1 19
7. T. Sakaeda, K. Kadoyama, and Y. Okuno Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system PLoS One 6 2011 e28124
8. FDA Drug Safety Communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. http://www.fda.gov/drugs/drugsafety/ucm256581.htm. Accessed January 26, 2014.
9. K.A. Sewright, P.M. Clarkson, and P.D. Thompson Statin myopathy: incidence, risk factors, and pathophysiology Curr Atheroscler Rep 9 2007 389 396
10. A. Gupta, and P.D. Thompson The relationship of vitamin D deficiency to statin myopathy Atherosclerosis 215 2011 23 29
11. C.J. Glueck, C. Abuchaibe, and P. Wang Symptomatic myositis-myalgia in hypercholesterolemic statin-treated patients with concurrent vitamin D deficiency leading to statin intolerance may reflect a reversible interaction between vitamin D deficiency and statins on skeletal muscle Med Hypotheses 77 2011 658 661
12. W. Ahmed, N. Khan, and C.J. Glueck et al. Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients Transl Res 153 2009 11 16
13. J.H. Lee, J.H. O'Keefe, D. Bell, D.D. Hensrud, and M.F. Holick Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol 52 2008 1949 1956
14. I.J. Riphagen, E. van der Veer, F.A. Muskiet, and M.J. DeJongste Myopathy during statin therapy in the daily practice of an outpatient cardiology clinic: prevalence, predictors and relation with vitamin D Curr Med Res Opin 28 2012 1247 1252
15. G. Fernandez, E.S. Spatz, C. Jablecki, and P.S. Phillips Statin myopathy: a common dilemma not reflected in clinical trials Cleve Clin J Med 78 2011 393 403
16. J.M. McKenney, M.H. Davidson, T.A. Jacobson, and J.R. Guyton Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force Am J Cardiol 97 2006 89C 94C